Skip to main content
Erschienen in: Current Hypertension Reports 1/2014

01.01.2014 | Therapeutic Trials (B Pitt, Section Editor)

Should African Americans with Hypertension Be Treated Differently than Non-African Americans?

verfasst von: John M. Flack, Brian A. Ference, Phillip Levy

Erschienen in: Current Hypertension Reports | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

African Americans have a higher burden of hypertension, more severe blood pressure (BP) elevations, more concurrent risk-enhancing co-morbidities (e.g., diabetes), sub-clinical vascular injury at lower non-hypertensive BP levels, lower BP control rates, and significantly greater risk for adverse pressure-related clinical complications (e.g., stroke, heart failure) than whites. Randomized prospective data from hypertension endpoint trials show a virtually identical percentage reduction in CVD risk for a given magnitude of BP lowering, irrespective of the presence or absence of pre-treatment CVD across a broad range of BP down to pre-treatment BP levels of 110/70 mm Hg. These data, mostly emanating from white populations, do not necessarily inform practitioners as to the level below which BP should be lowered in those with established, long-standing hypertension; however, these data do provide support for initiating hypertension treatment at lower than conventional BP thresholds. A Mendelian randomized study examining the impact of life-long lower SBP levels showed that lifelong exposure to 10 mm Hg lower SBP was associated with an 82 % lesser rate of SBP rise per decade and a 58 % lower CHD risk that was much greater than the 22 % reduction in CHD reported for the same magnitude of SBP reduction in clinical trials. Arguably, it is the hypertension treatment paradigm that merits reexamination. Earlier hypertension treatment in all populations prior to the onset of significant pressure-related target organ injury might conceivably prevent, or at least significantly attenuate, the well documented age-related rise in BP seen in most Western societies. In addition, this treatment paradigm might also reduce the significant residual CVD risk observed under the current recommended approach to hypertension treatment. This new approach to therapy would likely have substantial clinical and public health benefits in the high-risk, under-treated African American population that suffers outsized devastating consequences from inadequate control of BP.
Literatur
1.
Zurück zum Zitat Stein CM, Lang CC, Nelson R, Brown M, Wood AJ. Vasodilation in black Americans. Attenauted nitric oxide-mediated responses. Clin Pharmacol Ther. 1997;62:436–43.PubMedCrossRef Stein CM, Lang CC, Nelson R, Brown M, Wood AJ. Vasodilation in black Americans. Attenauted nitric oxide-mediated responses. Clin Pharmacol Ther. 1997;62:436–43.PubMedCrossRef
2.
Zurück zum Zitat Zion AS, Bond V, Adams RG, Williams, Fullilove RE, Sloan RP, et al. Low arterial compliance in young African American males. Am J Physiol Heart Circ Physiol. 2003;285:H457–62.PubMed Zion AS, Bond V, Adams RG, Williams, Fullilove RE, Sloan RP, et al. Low arterial compliance in young African American males. Am J Physiol Heart Circ Physiol. 2003;285:H457–62.PubMed
3.
Zurück zum Zitat Heffernan KS, Jae SY, Silund KR, Woods JA, Fernhall B. Racial differences in central blood pressure and vascular function in young men. Am J Physiol Heart Circ Physiol. 2008;295:H2380–7.PubMedCrossRef Heffernan KS, Jae SY, Silund KR, Woods JA, Fernhall B. Racial differences in central blood pressure and vascular function in young men. Am J Physiol Heart Circ Physiol. 2008;295:H2380–7.PubMedCrossRef
4.
Zurück zum Zitat Guo F, He D, Zhang W, Walton RG. Trends in Prevalence, Awareness, Management, and Control of Hypertension Among United States Adults, 1999 to 2010. J Am Coll Cardiol. 2012;60:599–606.PubMedCrossRef Guo F, He D, Zhang W, Walton RG. Trends in Prevalence, Awareness, Management, and Control of Hypertension Among United States Adults, 1999 to 2010. J Am Coll Cardiol. 2012;60:599–606.PubMedCrossRef
5.
Zurück zum Zitat Fiscella K, Holt K. Racial disparity in hypertension control: tallying the death toll. Am Fam Med. 2008;6:497–502.CrossRef Fiscella K, Holt K. Racial disparity in hypertension control: tallying the death toll. Am Fam Med. 2008;6:497–502.CrossRef
6.
Zurück zum Zitat Mensah GA, Mokdad AH, Ford ES, Greenlund KJ, Croft JB. State of disparities in cardiovascular health in the United States. Circulation. 2005;11:1233–41.CrossRef Mensah GA, Mokdad AH, Ford ES, Greenlund KJ, Croft JB. State of disparities in cardiovascular health in the United States. Circulation. 2005;11:1233–41.CrossRef
7.
Zurück zum Zitat East MA, Peterson ED, Shaw LK, Gattis WA, O’Connor CM. Racial differences in the outcomes of patients with diastolic heart failure. Am Heart J. 2004;1148:151–6.CrossRef East MA, Peterson ED, Shaw LK, Gattis WA, O’Connor CM. Racial differences in the outcomes of patients with diastolic heart failure. Am Heart J. 2004;1148:151–6.CrossRef
8.
Zurück zum Zitat Flack JM, Neaton JD, Damiels B, Esunge P. Ethnicity and renal disease: lessons from Multiple Risk Factor Intervention Trial and the Treatment of Mild Hypertension Study. Am J Kidney Dis. 1993;21(suppl):31–40.PubMed Flack JM, Neaton JD, Damiels B, Esunge P. Ethnicity and renal disease: lessons from Multiple Risk Factor Intervention Trial and the Treatment of Mild Hypertension Study. Am J Kidney Dis. 1993;21(suppl):31–40.PubMed
9.
Zurück zum Zitat Zhang X, Saaddine JB. Chou C_F, Cotch MF, et al. Prevalence of diabetic retinopathy in the United States, 2005–2008. JAMA. 2010;304(6):649–56.PubMedCentralPubMedCrossRef Zhang X, Saaddine JB. Chou C_F, Cotch MF, et al. Prevalence of diabetic retinopathy in the United States, 2005–2008. JAMA. 2010;304(6):649–56.PubMedCentralPubMedCrossRef
10.•
Zurück zum Zitat Allen N, Berry JD, Ning H, Van Horn L, et al. Impact of blood pressure and blood pressure change during middle age on the remaining lifetime risk for cardiovascular disease: the cardiovascular lifetime risk pooling project. Circulation. 2012;125(1):37–44.PubMedCentralPubMedCrossRef Allen N, Berry JD, Ning H, Van Horn L, et al. Impact of blood pressure and blood pressure change during middle age on the remaining lifetime risk for cardiovascular disease: the cardiovascular lifetime risk pooling project. Circulation. 2012;125(1):37–44.PubMedCentralPubMedCrossRef
11.
Zurück zum Zitat Franklin SS, Gustin 4th W, Wong ND, et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation. 1997;96(1):308–15.PubMedCrossRef Franklin SS, Gustin 4th W, Wong ND, et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation. 1997;96(1):308–15.PubMedCrossRef
12.
Zurück zum Zitat Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA. 2002;287(8):1003–10.PubMedCrossRef Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA. 2002;287(8):1003–10.PubMedCrossRef
13.
Zurück zum Zitat Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–13.PubMedCrossRef Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–13.PubMedCrossRef
14.
Zurück zum Zitat Carvalho JJ, Baruzzi RG, Howard PF, et al. Blood pressure in four remote populations in the INTERSALT Study. Hypertension. 1989;14:238–46.PubMedCrossRef Carvalho JJ, Baruzzi RG, Howard PF, et al. Blood pressure in four remote populations in the INTERSALT Study. Hypertension. 1989;14:238–46.PubMedCrossRef
15.
Zurück zum Zitat Wu M, Ware JH, Feinleib M. On the relation between blood pressure change and initial value. J Chron Dis. 1980;33(10):637–44.PubMedCrossRef Wu M, Ware JH, Feinleib M. On the relation between blood pressure change and initial value. J Chron Dis. 1980;33(10):637–44.PubMedCrossRef
17.
Zurück zum Zitat Julius S, Nesbitt SD, Egan BM, et al. Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354(16):1685–97.PubMedCrossRef Julius S, Nesbitt SD, Egan BM, et al. Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354(16):1685–97.PubMedCrossRef
18.
Zurück zum Zitat Julius S, Kaciroti N, Egan BM, Nesbitt S, Michelson EL, Trial of Preventing Hypertension (TROPHY) Investigators. TROPHY study: Outcomes based on the Seventh Report of the Joint National Committee on Hypertension definition of hypertension. J Am Soc Hypertens. 2008;2(1):39–43.PubMedCrossRef Julius S, Kaciroti N, Egan BM, Nesbitt S, Michelson EL, Trial of Preventing Hypertension (TROPHY) Investigators. TROPHY study: Outcomes based on the Seventh Report of the Joint National Committee on Hypertension definition of hypertension. J Am Soc Hypertens. 2008;2(1):39–43.PubMedCrossRef
19.
Zurück zum Zitat Lüders S, Schrader J, Berger J, et al. PHARAO Study Group. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens. 2008;26(7):1487–96.PubMedCrossRef Lüders S, Schrader J, Berger J, et al. PHARAO Study Group. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens. 2008;26(7):1487–96.PubMedCrossRef
20.
Zurück zum Zitat Law MR. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomized trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:1–19.CrossRef Law MR. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomized trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:1–19.CrossRef
21.
Zurück zum Zitat International Consortium for Blood Pressure Genome-Wide Association Studies, Ehret GB, Munroe PB, Rice KM, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478(7367):103–9.PubMedCrossRef International Consortium for Blood Pressure Genome-Wide Association Studies, Ehret GB, Munroe PB, Rice KM, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478(7367):103–9.PubMedCrossRef
22.
Zurück zum Zitat Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey SG. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27:1133–63.PubMedCrossRef Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey SG. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27:1133–63.PubMedCrossRef
23.
Zurück zum Zitat Ference BA, Yoo W, Alesh I, et al. Effect of Long Term Reduction in LDL-C Beginning Early in Life on the Risk of Coronary Heart Disease: A Mendelian Randomization Study. J Am Coll Cardiol. 2012;60(25):2631–9.PubMedCrossRef Ference BA, Yoo W, Alesh I, et al. Effect of Long Term Reduction in LDL-C Beginning Early in Life on the Risk of Coronary Heart Disease: A Mendelian Randomization Study. J Am Coll Cardiol. 2012;60(25):2631–9.PubMedCrossRef
24.••
Zurück zum Zitat Ference BA, Mahajan N, Julius S, et al. Effect of Naturally Random Allocation to Lower Blood Pressure Beginning before the Development of Hypertension. J Am Coll Cardiol. 2013; 61(10S). This reference quantifies the lifetime risk of CVD as being much less for a given magnitude of lower lifetime BP than for the same magnitude lower BP lowering observed in pharmacological trials of BP lowering in middle-aged to older adults. This observation provides information that is unlikely to ever be obtained from a randomized clinical trial. Ference BA, Mahajan N, Julius S, et al. Effect of Naturally Random Allocation to Lower Blood Pressure Beginning before the Development of Hypertension. J Am Coll Cardiol. 2013; 61(10S). This reference quantifies the lifetime risk of CVD as being much less for a given magnitude of lower lifetime BP than for the same magnitude lower BP lowering observed in pharmacological trials of BP lowering in middle-aged to older adults. This observation provides information that is unlikely to ever be obtained from a randomized clinical trial.
25.••
Zurück zum Zitat Flack JM, Sica DA, Bakris G, Brown AL, et al. Management of high blood pressure in blacks. An update of the International Society on Hypertension in Blacks Consensus Statement. Hypertension. 2010;56:780–800. This reference recommended a lower than conventional BP target/threshold (135/85 mm Hg) for initiation of pharmacological hypertension treatment in African Americans.PubMedCrossRef Flack JM, Sica DA, Bakris G, Brown AL, et al. Management of high blood pressure in blacks. An update of the International Society on Hypertension in Blacks Consensus Statement. Hypertension. 2010;56:780–800. This reference recommended a lower than conventional BP target/threshold (135/85 mm Hg) for initiation of pharmacological hypertension treatment in African Americans.PubMedCrossRef
26.•
Zurück zum Zitat ACCORD Study Group. Effects of intensive blood pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–85. The ACCORD study has been interpreted as “negative” because the underpowered primary composite CVD endpoint was insignificantly reduced in the low (SBP < 120) versus standard (SBP <140) group despite the fact that the pre-specified secondary endpoint stroke was significantly reduced by aggressive BP treatment. This is an important study to consider when making therapeutic recommendations for a stroke-prone population such as African Americans.CrossRef ACCORD Study Group. Effects of intensive blood pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–85. The ACCORD study has been interpreted as “negative” because the underpowered primary composite CVD endpoint was insignificantly reduced in the low (SBP < 120) versus standard (SBP <140) group despite the fact that the pre-specified secondary endpoint stroke was significantly reduced by aggressive BP treatment. This is an important study to consider when making therapeutic recommendations for a stroke-prone population such as African Americans.CrossRef
27.
Zurück zum Zitat Wright JT, Bakris G, Greene T, Agodoa LY, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial. JAMA. 2002;288:2421–31.PubMedCrossRef Wright JT, Bakris G, Greene T, Agodoa LY, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial. JAMA. 2002;288:2421–31.PubMedCrossRef
28.
Zurück zum Zitat Chobanian AV, Bakris GL, Black HR, Cushman WC, National High Blood Pressure Education Program Coordinating Committee, et al. Seventh report of the Joint National committee on Prevention, Detection, Evaluation , and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–52.PubMedCrossRef Chobanian AV, Bakris GL, Black HR, Cushman WC, National High Blood Pressure Education Program Coordinating Committee, et al. Seventh report of the Joint National committee on Prevention, Detection, Evaluation , and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–52.PubMedCrossRef
29.
Zurück zum Zitat American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care 2013;36 Suppl1:S11-S66 American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care 2013;36 Suppl1:S11-S66
30.
Zurück zum Zitat Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61(3):1086–97.PubMedCrossRef Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61(3):1086–97.PubMedCrossRef
31.
Zurück zum Zitat Appel LJ, Wright Jr JT. Greene, Agodoa LY, et al. Intensive blood pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010;363:918–29.PubMedCentralPubMedCrossRef Appel LJ, Wright Jr JT. Greene, Agodoa LY, et al. Intensive blood pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010;363:918–29.PubMedCentralPubMedCrossRef
32.
Zurück zum Zitat Jamerson K, Weber MA, Bakris G, Dahlof B, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417–28.PubMedCrossRef Jamerson K, Weber MA, Bakris G, Dahlof B, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417–28.PubMedCrossRef
Metadaten
Titel
Should African Americans with Hypertension Be Treated Differently than Non-African Americans?
verfasst von
John M. Flack
Brian A. Ference
Phillip Levy
Publikationsdatum
01.01.2014
Verlag
Springer US
Erschienen in
Current Hypertension Reports / Ausgabe 1/2014
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-013-0409-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.